# SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.

> **NCT06614322** · PHASE2 · RECRUITING · sponsor: **University of Rochester** · enrollment: 190 (estimated)

## Conditions studied

- Painful Peripheral Neuropathy
- Diabetic Peripheral Neuropathic Pain (DPN)
- Chemotherapy Induced Peripheral Neuropathy (CIPN)
- Idiopathic Peripheral Neuropathy

## Interventions

- **DRUG:** Pregabalin
- **DRUG:** Duloxetine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06614322
- **Lead sponsor:** University of Rochester
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-29
- **Primary completion:** 2028-06
- **Final completion:** 2028-06
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06614322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06614322, "SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT06614322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*